S&P 500   4,575.36 (+0.01%)
DOW   35,655.20 (-0.28%)
QQQ   381.28 (+0.57%)
AAPL   149.26 (-0.04%)
MSFT   322.88 (+4.12%)
FB   314.68 (-0.36%)
GOOGL   2,940.26 (+5.53%)
TSLA   1,057.34 (+3.82%)
AMZN   3,392.95 (+0.50%)
NVDA   249.10 (+0.78%)
BABA   168.79 (-0.71%)
NIO   39.88 (-1.46%)
CGC   12.98 (-1.44%)
GE   103.84 (-3.35%)
AMD   125.55 (+2.13%)
MU   68.46 (-0.70%)
T   25.18 (-0.75%)
F   15.72 (-1.38%)
ACB   6.93 (-1.42%)
DIS   169.70 (-1.36%)
PFE   42.83 (-1.68%)
BA   206.46 (-1.60%)
AMC   35.33 (-2.00%)
S&P 500   4,575.36 (+0.01%)
DOW   35,655.20 (-0.28%)
QQQ   381.28 (+0.57%)
AAPL   149.26 (-0.04%)
MSFT   322.88 (+4.12%)
FB   314.68 (-0.36%)
GOOGL   2,940.26 (+5.53%)
TSLA   1,057.34 (+3.82%)
AMZN   3,392.95 (+0.50%)
NVDA   249.10 (+0.78%)
BABA   168.79 (-0.71%)
NIO   39.88 (-1.46%)
CGC   12.98 (-1.44%)
GE   103.84 (-3.35%)
AMD   125.55 (+2.13%)
MU   68.46 (-0.70%)
T   25.18 (-0.75%)
F   15.72 (-1.38%)
ACB   6.93 (-1.42%)
DIS   169.70 (-1.36%)
PFE   42.83 (-1.68%)
BA   206.46 (-1.60%)
AMC   35.33 (-2.00%)
S&P 500   4,575.36 (+0.01%)
DOW   35,655.20 (-0.28%)
QQQ   381.28 (+0.57%)
AAPL   149.26 (-0.04%)
MSFT   322.88 (+4.12%)
FB   314.68 (-0.36%)
GOOGL   2,940.26 (+5.53%)
TSLA   1,057.34 (+3.82%)
AMZN   3,392.95 (+0.50%)
NVDA   249.10 (+0.78%)
BABA   168.79 (-0.71%)
NIO   39.88 (-1.46%)
CGC   12.98 (-1.44%)
GE   103.84 (-3.35%)
AMD   125.55 (+2.13%)
MU   68.46 (-0.70%)
T   25.18 (-0.75%)
F   15.72 (-1.38%)
ACB   6.93 (-1.42%)
DIS   169.70 (-1.36%)
PFE   42.83 (-1.68%)
BA   206.46 (-1.60%)
AMC   35.33 (-2.00%)
S&P 500   4,575.36 (+0.01%)
DOW   35,655.20 (-0.28%)
QQQ   381.28 (+0.57%)
AAPL   149.26 (-0.04%)
MSFT   322.88 (+4.12%)
FB   314.68 (-0.36%)
GOOGL   2,940.26 (+5.53%)
TSLA   1,057.34 (+3.82%)
AMZN   3,392.95 (+0.50%)
NVDA   249.10 (+0.78%)
BABA   168.79 (-0.71%)
NIO   39.88 (-1.46%)
CGC   12.98 (-1.44%)
GE   103.84 (-3.35%)
AMD   125.55 (+2.13%)
MU   68.46 (-0.70%)
T   25.18 (-0.75%)
F   15.72 (-1.38%)
ACB   6.93 (-1.42%)
DIS   169.70 (-1.36%)
PFE   42.83 (-1.68%)
BA   206.46 (-1.60%)
AMC   35.33 (-2.00%)
NASDAQ:NLNK

NewLink Genetics Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$9.14
+0.12 (+1.33 %)
(As of 10/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$8.99
$9.31
50-Day Range
$0.89
$14.10
52-Week Range
$0.82
$3.60
Volume9,439 shs
Average Volume547,540 shs
Market Capitalization$341.18 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17

Receive NLNK News and Ratings via Email

Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter.


NewLink Genetics logo

About NewLink Genetics

NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NLNK
CUSIP
65151110
Employees
55
Year Founded
N/A

Sales & Book Value

Annual Sales
$940,000.00
Book Value
$2.11 per share

Profitability

Net Income
$-42.99 million
Net Margins
-4,592.84%

Debt

Price-To-Earnings

Miscellaneous

Market Cap
$341.18 million
Next Earnings Date
N/A
Optionable
Optionable

MarketRank

Overall MarketRank

1.13 out of 5 stars

Medical Sector

1192nd out of 1,363 stocks

Pharmaceutical Preparations Industry

575th out of 667 stocks

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












NewLink Genetics (NASDAQ:NLNK) Frequently Asked Questions

What stocks does MarketBeat like better than NewLink Genetics?

Wall Street analysts have given NewLink Genetics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but NewLink Genetics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were NewLink Genetics' earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) released its earnings results on Wednesday, November, 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, hitting the Zacks' consensus estimate of ($0.27). The biotechnology company earned $0.25 million during the quarter. NewLink Genetics had a negative trailing twelve-month return on equity of 41.50% and a negative net margin of 4,592.84%.
View NewLink Genetics' earnings history
.

Who are NewLink Genetics' key executives?

NewLink Genetics' management team includes the following people:
  • Dr. Charles J. Link Jr., Co-Founder, Chairman, CEO & Chief Scientific Officer (Age 60)
  • Mr. Nicholas N. Vahanian, Co-Founder, Pres, Chief Medical Officer & Director (Age 52)
  • Dr. Eugene P. Kennedy M.D., FACS, Chief Medical Officer (Age 50)
  • Mr. Brian Wiley, Chief Commercial Officer (Age 51)
  • Mr. Carl W. Langren, CFO & Principal Accounting Officer (Age 64)

What other stocks do shareholders of NewLink Genetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NewLink Genetics investors own include Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Novavax (NVAX), SunPower (SPWR), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), Cara Therapeutics (CARA) and Gilead Sciences (GILD).

What is NewLink Genetics' stock symbol?

NewLink Genetics trades on the NASDAQ under the ticker symbol "NLNK."

What is NewLink Genetics' stock price today?

One share of NLNK stock can currently be purchased for approximately $9.14.

How much money does NewLink Genetics make?

NewLink Genetics has a market capitalization of $341.18 million and generates $940,000.00 in revenue each year. The biotechnology company earns $-42.99 million in net income (profit) each year or ($1.03) on an earnings per share basis.

How many employees does NewLink Genetics have?

NewLink Genetics employs 55 workers across the globe.

What is NewLink Genetics' official website?

The official website for NewLink Genetics is www.newlinkgenetics.com.

Where are NewLink Genetics' headquarters?

NewLink Genetics is headquartered at 2503 SOUTH LOOP DRIVE, AMES IA, 50010.

How can I contact NewLink Genetics?

NewLink Genetics' mailing address is 2503 SOUTH LOOP DRIVE, AMES IA, 50010. The biotechnology company can be reached via phone at 515-296-5555 or via email at [email protected].


This page was last updated on 10/27/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.